COMPANY

Akros Pharma Inc.

HQ: Princeton, NJ source · akrospharma.com ↗

Profile checked Oct 10, 2026

Keywords: Plaque Psoriasis Skin Diseases Anemia of Chronic Kidney Disease Dyslipidemia Type 2 Diabetes Mellitus Psoriasis Diabetes Mellitus Type II Diabetes Mellitus Cryopyrin-associated Periodic Syndromes Chronic Heart Failure Rheumatoid Arthritis Pulmonary Arterial Hypertension Anemia in Chronic Kidney Disease Response to Therapy of Hepatitis C Virus Infection Type II Hyperlipidemia JTZ-951 JTT-302 JTE-051 JTE-162 JTT-861 JTT-662 JTE-451 JTT-251 JTZ-951, 14C-JTZ-951 JTT-252 JTT-851 JTT-654 JTT-130 JTK-853

25Trials (company is sponsor)

Timeline

Feb 2, 2026 Trial start Phase 1: Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS) source ↗
Dec 20, 2023 Trial start Phase 2: Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction source ↗
Jun 15, 2020 Trial start Phase 1: Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes source ↗
2019-03 Trial start Phase 2: Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension source ↗
Jan 17, 2019 Trial start Phase 2: Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis source ↗
Nov 10, 2017 Trial start Phase 2: Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis source ↗
2016-12 Trial start Phase 1: Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects source ↗
Sep 14, 2016 Trial start Phase 2: Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis source ↗
2016-06 Trial start Phase 1: Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis source ↗
2015-10 Trial start Phase 1: Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease source ↗
2014-04 Trial start Phase 1: Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252 source ↗
2014-03 Trial start Phase 1: Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects source ↗
2013-10 Trial start Phase 1: Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease source ↗
2013-05 Trial start Phase 1: Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease source ↗
2012-09 Trial start Phase 2: Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus source ↗
2010-08 Trial start Phase 1: Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected Subjects source ↗
2010-03 Trial start Phase 1: Two Week Study Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Doses of JTK-853 in Healthy Subjects source ↗
2010-01 Trial start Phase 1: Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects source ↗
2009-09 Trial start Phase 2: Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients source ↗
2009-06 Trial start Phase 2: Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients source ↗
2007-01 Trial start Phase 2: Safety Study of JTT-302 in Subjects With Low HDL-C Levels source ↗
2006-12 Trial start Phase 2: Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels source ↗
2004-02 Trial start Phase 2: Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels source ↗
2004-01 Trial start Phase 2: Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels source ↗
2002-06 Trial start Phase 2: Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia source ↗

Clinical trials (lead sponsor) 25

Record	Title	Phase	Status	Start	Primary completion
NCT07247266	Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)	Phase 1	Completed	Feb 2, 2026	Sep 9, 2026 (actual)
NCT06017609	Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction	Phase 2	Completed	Dec 20, 2023	May 18, 2026 (actual)
NCT04465877	Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes	Phase 1	Completed	Jun 15, 2020	Feb 17, 2021 (actual)
NCT03832738	Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis	Phase 2	Completed	Jan 17, 2019	Mar 13, 2020 (actual)
NCT03358290	Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis	Phase 2	Terminated	Nov 10, 2017	Oct 29, 2018 (actual)
NCT02919475	Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis	Phase 2	Completed	Sep 14, 2016	Jun 25, 2018 (actual)
NCT03789643	Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension	Phase 2	Withdrawn	2019-03	2021-03 (estimated)
NCT03018509	Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects	Phase 1	Completed	2016-12	Jun 20, 2017 (actual)
NCT02805244	Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis	Phase 1	Completed	2016-06	2016-09 (actual)
NCT02581124	Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease	Phase 1	Completed	2015-10	2016-04 (actual)
NCT02120976	Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252	Phase 1	Terminated	2014-04	2015-02 (actual)
NCT02106585	Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects	Phase 1	Completed	2014-03	2014-08 (actual)
NCT01971164	Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease	Phase 1	Completed	2013-05	2014-05 (actual)
NCT01978587	Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease	Phase 1	Completed	2013-10	2013-12 (actual)
NCT01699737	Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus	Phase 2	Completed	2012-09	2013-05 (actual)
NCT00749788	Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels	Phase 2	Completed	2006-12	2008-02 (actual)
NCT00997152	Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients	Phase 2	Terminated	2009-09	2010-03 (actual)
NCT00748852	Safety Study of JTT-302 in Subjects With Low HDL-C Levels	Phase 2	Completed	2007-01	2008-03 (actual)
NCT00929539	Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients	Phase 2	Completed	2009-06	2010-05 (actual)
NCT01475981	Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects	Phase 1	Completed	2010-01	2010-04 (actual)
NCT01473069	Two Week Study Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Doses of JTK-853 in Healthy Subjects	Phase 1	Terminated	2010-03	2010-07 (actual)
NCT01473056	Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected Subjects	Phase 1	Completed	2010-08	2010-10 (actual)
NCT00689442	Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels	Phase 2	Completed	2004-01	2004-11 (actual)
NCT00688896	Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia	Phase 2	Completed	2002-06	2003-04 (actual)
NCT00688558	Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels	Phase 2	Completed	2004-02	2004-12 (actual)